{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T21:54:50Z","timestamp":1792446890482,"version":"4.5.0"},"reference-count":120,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T00:00:00Z","timestamp":1722384000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T00:00:00Z","timestamp":1722384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Major depressive disorder (MDD), commonly known as depression, affects over 300 million people worldwide as of 2018 and presents a wide range of clinical symptoms. The international clinical trials registry platform (ICTRP) introduced by WHO includes aggregated data from ClinicalTrials.gov and 17 other national registers, making it the largest clinical trial platform. Here we analysed data in ICTRP with the aim of providing comprehensive insights into clinical trials on depression. Applying a novel hidden duplicate identification method, 10,606 depression trials were identified in ICTRP, with ANZCTR being the largest non- ClinicalTrials.gov database at 1031 trials, followed by IRCT with 576 trials, ISRCTN with 501 trials, CHiCTR with 489 trials, and EUCTR with 351 trials. The top four most studied drugs, ketamine, sertraline, duloxetine, and fluoxetine, were consistent in both groups, but ClinicalTrials.gov had more trials for each drug compared to the non-ClinicalTrials.gov group. Out of 9229 interventional trials, 663 unique agents were identified, including approved drugs (74.5%), investigational drugs (23.2%), withdrawn drugs (1.8%), nutraceuticals (0.3%), and illicit substances (0.2%). Both ClinicalTrials.gov and non-ClinicalTrials.gov databases revealed that the largest categories were antidepressive agents (1172 in ClinicalTrials.gov and 659 in non-ClinicalTrials.gov) and nutrients, amino acids, and chemical elements (250 in ClinicalTrials.gov and 659 in non-ClinicalTrials.gov), indicating a focus on alternative treatments involving dietary supplements and nutrients. Additionally, 26 investigational antidepressive agents targeting 16 different drug targets were identified, with buprenorphine (opioid agonist), saredutant (NK2 antagonist), and seltorexant (OX2 antagonist) being the most frequently studied. This analysis addresses 40 approved drugs for depression treatment including new drug classes like GABA modulators and NMDA antagonists that are offering new prospects for treating MDD, including drug-resistant depression and postpartum depression subtypes.<\/jats:p>","DOI":"10.1038\/s41398-024-03031-6","type":"journal-article","created":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T19:21:40Z","timestamp":1722453700000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Depression clinical trials worldwide: a systematic analysis of the ICTRP and comparison with ClinicalTrials.gov"],"prefix":"10.1038","volume":"14","author":[{"given":"Eugenia D.","family":"Namiot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Smirnovov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8549-1350","authenticated-orcid":false,"given":"Aleksandr V.","family":"Sokolov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir N.","family":"Chubarev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vadim V.","family":"Tarasov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7112-0921","authenticated-orcid":false,"given":"Helgi B.","family":"Schi\u00f6th","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,31]]},"reference":[{"key":"3031_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.31887\/DCNS.2020.22.1\/wgaebel","volume":"22","author":"W Gaebel","year":"2020","unstructured":"Gaebel W, Stricker J, Kerst A. Changes from ICD-10 to ICD-11 and future directions in psychiatric classification. Dialogues Clin Neurosci. 2020;22:7\u201315.","journal-title":"Dialogues Clin Neurosci"},{"key":"3031_CR2","doi-asserted-by":"crossref","unstructured":"Lim GY, Tam WW, Lu Y, Ho CS, Zhang MW, Ho RC. Prevalence of depression in the community from 30 countries between 1994 and 2014. Sci Rep. 2018;8:2861.","DOI":"10.1038\/s41598-018-21243-x"},{"key":"3031_CR3","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1016\/S0140-6736(21)02143-7","volume":"398","author":"DF Santomauro","year":"2021","unstructured":"Santomauro DF, Herrera AM, Shadid J, Zheng P, Ashbaugh C, Pigott DM, et al. Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. Lancet. 2021;398:1700\u201312.","journal-title":"Lancet"},{"key":"3031_CR4","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1007\/s11126-021-09930-x","volume":"92","author":"B Soares","year":"2021","unstructured":"Soares B, Kanevsky G, Teng CT, P\u00e9rez-Esparza R, Bonetto GG, Lacerda AL, et al. Prevalence and impact of treatment-resistant depression in Latin America: a prospective, observational study. Psychiatr Q. 2021;92:1797\u2013815.","journal-title":"Psychiatr Q"},{"key":"3031_CR5","doi-asserted-by":"crossref","unstructured":"Goldberg JS, Bell Jr CE, Pollard DA. Revisiting the monoamine hypothesis of depression: a new perspective. Perspect Med Chem. 2014;6:PMC-S11375.","DOI":"10.4137\/PMC.S11375"},{"key":"3031_CR6","first-page":"25","volume":"13","author":"JB Weilburg","year":"2004","unstructured":"Weilburg JB. An overview of SSRI and SNRI therapies for depression. Managed Care. 2004;13:25\u201333.","journal-title":"Managed Care"},{"key":"3031_CR7","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1111\/j.1365-2710.2009.01050.x","volume":"35","author":"M Machado","year":"2010","unstructured":"Machado M, Einarson TR. Comparison of SSRIs and SNRIs in major depressive disorder: a meta\u2010analysis of head\u2010 to\u2010 head randomized clinical trials. J Clin Pharm Ther 2010;35:177\u201388.","journal-title":"J Clin Pharm Ther"},{"key":"3031_CR8","doi-asserted-by":"publisher","first-page":"732","DOI":"10.2174\/1570159X14666151208113700","volume":"14","author":"O Kohler","year":"2016","unstructured":"Kohler O, Krogh J, Mors O, Eriksen Benros M. Inflammation in depression and the potential for anti-inflammatory treatment. Curr Neuropharmacol. 2016;14:732\u201342.","journal-title":"Curr Neuropharmacol"},{"key":"3031_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jad.2020.01.102","volume":"266","author":"K Sanada","year":"2020","unstructured":"Sanada K, Nakajima S, Kurokawa S, Barcel\u00f3-Soler A, Ikuse D, Hirata A, et al. Gut microbiota and major depressive disorder: A systematic review and meta-analysis. J Affect Disord. 2020;266:1\u201313.","journal-title":"J Affect Disord"},{"key":"3031_CR10","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1017\/S0033291719001454","volume":"49","author":"EF Osimo","year":"2019","unstructured":"Osimo EF, Baxter LJ, Lewis G, Jones PB, Khandaker GM. Prevalence of low-grade inflammation in depression: a systematic review and meta-analysis of CRP levels. Psychol Med. 2019;49:1958\u201370.","journal-title":"Psychol Med"},{"key":"3031_CR11","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.biopsych.2009.09.033","volume":"67","author":"Y Dowlati","year":"2010","unstructured":"Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry. 2010;67:446\u201357.","journal-title":"Biol Psychiatry"},{"key":"3031_CR12","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.jad.2011.08.003","volume":"139","author":"Y Liu","year":"2012","unstructured":"Liu Y, Ho RC, Mak A. Interleukin (IL)-6, tumour necrosis factor alpha (TNF-\u03b1) and soluble interleukin-2 receptors (sIL-2R) are elevated in patients with major depressive disorder: a meta-analysis and meta-regression. J Affect Disord. 2012;139:230\u20139.","journal-title":"J Affect Disord"},{"key":"3031_CR13","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1001\/jamapsychiatry.2014.1611","volume":"71","author":"O K\u00f6hler","year":"2014","unstructured":"K\u00f6hler O, Benros ME, Nordentoft M, Farkouh ME, Iyengar RL, Mors O, et al. Effect of anti- inflammatory treatment on depression, depressive symptoms, and adverse effects: a systematic review and meta-analysis of randomized clinical trials. JAMA Psychiatry. 2014;71:1381\u201391.","journal-title":"JAMA Psychiatry"},{"key":"3031_CR14","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0140-6736(05)67763-X","volume":"367","author":"S Tyring","year":"2006","unstructured":"Tyring S, Gottlieb A, Papp K, Gordon K, Leonardi C, Wang A, et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet. 2006;367:29\u201335.","journal-title":"Lancet"},{"key":"3031_CR15","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1177\/0269881115578160","volume":"29","author":"A Gougol","year":"2015","unstructured":"Gougol A, Zareh-Mohammadi N, Raheb S, Farokhnia M, Salimi S, Iranpour N, et al. Simvastatin as an adjuvant therapy to fluoxetine in patients with moderate to severe major depression: A double-blind placebo-controlled trial. J Psychopharmacol. 2015;29:575\u201381.","journal-title":"J Psychopharmacol."},{"key":"3031_CR16","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1111\/acps.13016","volume":"139","author":"O K\u00f6hler-Forsberg","year":"2019","unstructured":"K\u00f6hler-Forsberg O, N Lydholm C, Hjorth\u00f8j C, Nordentoft M, Mors O, Benros ME. Efficacy of anti\u2010 inflammatory treatment on major depressive disorder or depressive symptoms: meta\u2010 analysis of clinical trials. Acta Psychiatr Scand. 2019;139:404\u201319.","journal-title":"Acta Psychiatr Scand"},{"key":"3031_CR17","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.pnpbp.2012.02.002","volume":"37","author":"T Miyaoka","year":"2012","unstructured":"Miyaoka T, Wake R, Furuya M, Liaury K, Ieda M, Kawakami K, et al. Minocycline as adjunctive therapy for patients with unipolar psychotic depression: an open-label study. Prog Neuropsychopharmacol Biol Psychiatry. 2012;37:222\u20136.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"3031_CR18","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1111\/acps.12978","volume":"139","author":"L Ohlsson","year":"2019","unstructured":"Ohlsson L, Gustafsson A, Lavant E, Suneson K, Brundin L, Westrin \u00c5, et al. Leaky gut biomarkers in depression and suicidal behavior. Acta Psychiatr Scand. 2019;139:185\u201393.","journal-title":"Acta Psychiatr Scand"},{"key":"3031_CR19","first-page":"117","volume":"29","author":"M Mass","year":"2008","unstructured":"Mass M, Kubera M, Leunis JC. The gut-brain barrier in major depression: intestinal mucosal dysfunction with an increased translocation of LPS from gram negative enterobacteria (leaky gut) plays a role in the inflammatory pathophysiology of depression. Neuroendocrinol Lett. 2008;29:117\u201324.","journal-title":"Neuroendocrinol Lett"},{"key":"3031_CR20","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.nut.2015.09.003","volume":"32","author":"G Akkasheh","year":"2016","unstructured":"Akkasheh G, Kashani-Poor Z, Tajabadi-Ebrahimi M, Jafari P, Akbari H, Taghizadeh M, et al. Clinical and metabolic response to probiotic administration in patients with major depressive disorder: a randomized, double-blind, placebo-controlled trial. Nutrition. 2016;32:315\u201320.","journal-title":"Nutrition"},{"key":"3031_CR21","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.clnu.2018.04.010","volume":"38","author":"A Kazemi","year":"2019","unstructured":"Kazemi A, Noorbala AA, Azam K, Eskandari MH, Djafarian K. Effect of probiotic and prebiotic vs placebo on psychological outcomes in patients with major depressive disorder: a randomized clinical trial. Clin Nutr. 2019;38:522\u20138.","journal-title":"Clin Nutr"},{"key":"3031_CR22","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1017\/S0007114510004319","volume":"105","author":"M Messaoudi","year":"2011","unstructured":"Messaoudi M, Lalonde R, Violle N, Javelot H, Desor D, Nejdi A, et al. Assessment of psychotropic- like properties of a probiotic formulation (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) in rats and human subjects. Br J Nutr. 2011;105:755\u201364.","journal-title":"Br J Nutr"},{"key":"3031_CR23","doi-asserted-by":"publisher","first-page":"483","DOI":"10.3390\/nu8080483","volume":"8","author":"R Huang","year":"2016","unstructured":"Huang R, Wang K, Hu J. Effect of probiotics on depression: a systematic review and meta-analysis of randomized controlled trials. Nutrients. 2016;8:483.","journal-title":"Nutrients"},{"key":"3031_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2019.112568","volume":"282","author":"KK Goh","year":"2019","unstructured":"Goh KK, Liu YW, Kuo PH, Chung YC, Lu ML, Chen CH. Effect of probiotics on depressive symptoms: A meta-analysis of human studies. Psychiatry Res. 2019;282:112568.","journal-title":"Psychiatry Res"},{"key":"3031_CR25","doi-asserted-by":"publisher","first-page":"101","DOI":"10.3389\/fpsyt.2019.00101","volume":"10","author":"A Menke","year":"2019","unstructured":"Menke A. Is the HPA axis as target for depression outdated, or is there a new hope? Front Psychiatry. 2019;10:101.","journal-title":"Front Psychiatry"},{"key":"3031_CR26","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.3390\/brainsci11101298","volume":"11","author":"J Mikulska","year":"2021","unstructured":"Mikulska J, Juszczyk G, Gawro\u0144ska-Grzywacz M, Herbet M. HPA axis in the pathomechanism of depression and schizophrenia: new therapeutic strategies based on its participation. Brain Sci. 2021;11:1298.","journal-title":"Brain Sci"},{"key":"3031_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.psyneuen.2021.105625","volume":"136","author":"Z Zajkowska","year":"2022","unstructured":"Zajkowska Z, Gullett N, Walsh A, Zonca V, Pedersen GA, Souza L. et.al. Cortisol and development of depression in adolescence and young adulthood\u2013a systematic review and meta-analysis. Psychoneuroendocrinology. 2022;136:105625.","journal-title":"Psychoneuroendocrinology"},{"key":"3031_CR28","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1001\/archpsyc.61.12.1235","volume":"61","author":"H Jahn","year":"2004","unstructured":"Jahn H, Schick M, Kiefer F, Kellner M, Yassouridis A, Wiedemann K. Metyrapone as additive treatment in major depression: a double-blind and placebo-controlled trial. Arch Gen Psychiatry. 2004;61:1235\u201344.","journal-title":"Arch Gen Psychiatry"},{"key":"3031_CR29","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1097\/JCP.0000000000000744","volume":"37","author":"T Block","year":"2017","unstructured":"Block T, Petrides G, Kushner H, Kalin N, Belanoff J, Schatzberg A. Mifepristone plasma level and glucocorticoid receptor antagonism associated with response in patients with psychotic depression. J Clin Psychopharmacol. 2017;37:505\u201311.","journal-title":"J Clin Psychopharmacol"},{"key":"3031_CR30","doi-asserted-by":"crossref","unstructured":"Kaur M, Sanches M. Experimental therapeutics in treatment-resistant major depressive disorder J Exp Pharmacol. 2021;13:181\u201396.","DOI":"10.2147\/JEP.S259302"},{"key":"3031_CR31","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1002\/cmdc.201200137","volume":"7","author":"MV Schmidt","year":"2012","unstructured":"Schmidt MV, Paez Pereda M, Holsboer F, Hausch F. The prospect of FKBP51 as a drug target. ChemMedChem. 2012;7:1351\u20139.","journal-title":"ChemMedChem"},{"key":"3031_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1741-7015-11-28","volume":"11","author":"N Hepgul","year":"2013","unstructured":"Hepgul N, Cattaneo A, Zunszain PA, Pariante CM. Depression pathogenesis and treatment: what can we learn from blood mRNA expression? BMC Med. 2013;11:1\u201313.","journal-title":"BMC Med"},{"key":"3031_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/jnc.13033","volume":"133","author":"LJ Blair","year":"2015","unstructured":"Blair LJ, Baker JD, Sabbagh JJ, Dickey CA. The emerging role of peptidyl\u2010 prolyl isomerase chaperones in tau oligomerization, amyloid processing, and Alzheimer\u2019s disease. J Neurochem 2015;133:1\u201313.","journal-title":"J Neurochem"},{"key":"3031_CR34","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/npp.2015.235","volume":"41","author":"AS Zannas","year":"2016","unstructured":"Zannas AS, Wiechmann T, Gassen NC, Binder EB. Gene\u2013stress\u2013epigenetic regulation of FKBP5: clinical and translational implications. Neuropsychopharmacology. 2016;41:261\u201374.","journal-title":"Neuropsychopharmacology"},{"key":"3031_CR35","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/j.biopsych.2017.06.024","volume":"82","author":"BW Dunlop","year":"2017","unstructured":"Dunlop BW, Binder EB, Iosifescu D, Mathew SJ, Neylan TC, Pape JC, et al. Corticotropin-releasing factor receptor 1 antagonism is ineffective for women with posttraumatic stress disorder. Biol Psychiatry. 2017;82:866\u201374.","journal-title":"Biol Psychiatry"},{"key":"3031_CR36","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1007\/s00213-017-4556-2","volume":"234","author":"SR Spierling","year":"2017","unstructured":"Spierling SR, Zorrilla EP. Don\u2019t stress about CRF: assessing the translational failures of CRF 1 antagonists. Psychopharmacology. 2017;234:1467\u201381.","journal-title":"Psychopharmacology"},{"key":"3031_CR37","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1176\/appi.ajp.2008.07071199","volume":"165","author":"B Binneman","year":"2008","unstructured":"Binneman B, Feltner D, Kolluri S, Shi Y, Qiu R, Stiger T. A 6-week randomized, placebo-controlled trial of CP-316,311 (a selective CRH 1 antagonist) in the treatment of major depression. Am J Psychiatry. 2008;165:617\u201320.","journal-title":"Am J Psychiatry"},{"key":"3031_CR38","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/j.biopsych.2017.10.012","volume":"82","author":"JW Murrough","year":"2017","unstructured":"Murrough JW, Charney DS. Corticotropin-releasing factor type 1 receptor antagonists for stress- related disorders: time to call it quits? Biol Psychiatry. 2017;82:858\u201360.","journal-title":"Biol Psychiatry"},{"key":"3031_CR39","doi-asserted-by":"crossref","unstructured":"Asadi\u2010 Pooya AA, Malekpour M, Zamiri B, Kashkooli M, Firouzabadi N. FKBP5 blockade may provide a new horizon for the treatment of stress\u2010 associated disorders; an in\u2010 silico study. Epilepsia Open. 2023;8:633\u201340.","DOI":"10.1002\/epi4.12749"},{"key":"3031_CR40","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.3389\/fphar.2018.01425","volume":"9","author":"JM Kolos","year":"2018","unstructured":"Kolos JM, Voll AM, Bauder M, Hausch F. FKBP ligands\u2014where we are and where to go? Front Pharmacol. 2018;9:1425.","journal-title":"Front Pharmacol"},{"key":"3031_CR41","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1159\/000520554","volume":"91","author":"L Rink","year":"2022","unstructured":"Rink L, Adams A, Braun C, Bschor T, Kuhr K, Baethge C. Dose-response relationship in selective serotonin and norepinephrine reuptake inhibitors in the treatment of major depressive disorder: a meta- analysis and network meta-analysis of randomized controlled trials. Psychother Psychosom. 2022;91:84\u201393.","journal-title":"Psychother Psychosom"},{"key":"3031_CR42","doi-asserted-by":"publisher","first-page":"102770","DOI":"10.1016\/j.ctim.2021.102770","volume":"61","author":"R Altaf","year":"2021","unstructured":"Altaf R, Gonzalez I, Rubino K, Nemec EC II. Folate as adjunct therapy to SSRI\/SNRI for major depressive disorder: systematic review & meta-analysis. Complement Ther Med. 2021;61:102770.","journal-title":"Complement Ther Med"},{"key":"3031_CR43","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/S2215-0366(21)00154-1","volume":"8","author":"SE Murphy","year":"2021","unstructured":"Murphy SE, Capit\u00e3o LP, Giles SL, Cowen PJ, Stringaris A, Harmer CJ. The knowns and unknowns of SSRI treatment in young people with depression and anxiety: efficacy, predictors, and mechanisms of action. Lancet Psychiatry. 2021;8:824\u201335.","journal-title":"Lancet Psychiatry"},{"key":"3031_CR44","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s10787-020-00777-5","volume":"29","author":"V Dionisie","year":"2021","unstructured":"Dionisie V, Filip GA, Manea MC, Manea M, Riga S. The anti-inflammatory role of SSRI and SNRI in the treatment of depression: a review of human and rodent research studies. Inflammopharmacology. 2021;29:75\u201390.","journal-title":"Inflammopharmacology"},{"key":"3031_CR45","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1080\/17460441.2019.1546691","volume":"14","author":"X Gonda","year":"2019","unstructured":"Gonda X, Sharma SR, Tarazi FI. Vortioxetine: a novel antidepressant for the treatment of major depressive disorder. Expert Opin Drug Discov. 2019;14:81\u201389.","journal-title":"Expert Opin Drug Discov"},{"key":"3031_CR46","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.922648","volume":"13","author":"X Zhang","year":"2022","unstructured":"Zhang X, Cai Y, Hu X, Lu CY, Nie X, Shi L. Systematic review and meta-analysis of vortioxetine for the treatment of major depressive disorder in adults. Front Psychiatry. 2022;13:922648.","journal-title":"Front Psychiatry"},{"key":"3031_CR47","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1080\/09540261.2020.1854194","volume":"33","author":"LA Jelen","year":"2021","unstructured":"Jelen LA, Stone JM. Ketamine for depression. Int Rev Psychiatry. 2021;33:207\u201328.","journal-title":"Int Rev Psychiatry"},{"key":"3031_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2019.112367","volume":"379","author":"M Rinc\u00f3n-Cort\u00e9s","year":"2020","unstructured":"Rinc\u00f3n-Cort\u00e9s M, Grace AA. Antidepressant effects of ketamine on depression-related phenotypes and dopamine dysfunction in rodent models of stress. Behav Brain Res. 2020;379:112367.","journal-title":"Behav Brain Res"},{"key":"3031_CR49","doi-asserted-by":"crossref","unstructured":"Dronkers TM, Ouwehand AC, Rijkers GT. Global analysis of clinical trials with probiotics. Heliyon. 2020;6:e04467.","DOI":"10.1016\/j.heliyon.2020.e04467"},{"key":"3031_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41536-019-0082-7","volume":"4","author":"T Negoro","year":"2019","unstructured":"Negoro T, Okura H, Maehata M, Hayashi S, Yoshida S, Takada N, et al. Trends in clinical trials for stroke by cell therapy: data mining ClinicalTrials. gov and the ICTRP portal site. NPJ Regener Med. 2019;4:20.","journal-title":"NPJ Regener Med"},{"key":"3031_CR51","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.cpr.2018.09.004","volume":"67","author":"AJ Polo","year":"2019","unstructured":"Polo AJ, Makol BA, Castro AS, Col\u00f3n-Quintana N, Wagstaff AE, Guo S. Diversity in randomized clinical trials of depression: A 36-year review. Clin Psychol Rev. 2019;67:22\u201335.","journal-title":"Clin Psychol Rev"},{"key":"3031_CR52","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.jad.2016.03.016","volume":"198","author":"D Al-Karawi","year":"2016","unstructured":"Al-Karawi D, Jubair L. Bright light therapy for nonseasonal depression: meta-analysis of clinical trials. J Affect Disord. 2016;198:64\u201371.","journal-title":"J Affect Disord"},{"key":"3031_CR53","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1080\/14737175.2017.1283217","volume":"17","author":"RP Garay","year":"2017","unstructured":"Garay RP, Zarate CA Jr, Charpeaud T, Citrome L, Correll CU, Hameg A, et al. Investigational drugs in recent clinical trials for treatment-resistant depression. Expert Rev Neurother. 2017;17:593\u2013609.","journal-title":"Expert Rev Neurother"},{"key":"3031_CR54","doi-asserted-by":"publisher","first-page":"11076","DOI":"10.3390\/ijms231911076","volume":"23","author":"P Hu","year":"2022","unstructured":"Hu P, Lu Y, Pan BX, Zhang WH. New insights into the pivotal role of the amygdala in inflammation- related depression and anxiety disorder. J Mol Sci. 2022;23:11076.","journal-title":"J Mol Sci"},{"key":"3031_CR55","doi-asserted-by":"crossref","unstructured":"van der Heijden AR, Houben T. Lipids in major depressive disorder: new kids on the block or old friends revisited? Front Psychiatry. 2023;14.","DOI":"10.3389\/fpsyt.2023.1213011"},{"key":"3031_CR56","doi-asserted-by":"crossref","unstructured":"Namiot ED, Smirnovov\u00e1 D, Sokolov AV, Chubarev VN, Tarasov VV, Schi\u00f6th HB. The international clinical trials registry platform (ICTRP): data integrity and the trends in clinical trials, diseases, and drugs. Front Pharmacol. 2023;14:1213011.","DOI":"10.3389\/fphar.2023.1228148"},{"key":"3031_CR57","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1124\/pharmrev.121.000317","volume":"73","author":"AV Sokolov","year":"2021","unstructured":"Sokolov AV, Dostdar SA, Attwood MM, Krasilnikova AA, Ilina AA, Nabieva AS, et al. Brain cancer drug discovery: clinical trials, drug classes, targets, and combinatorial therapies. Pharmacol Rev. 2021;73:1172\u2013203.","journal-title":"Pharmacol Rev"},{"key":"3031_CR58","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/s41573-021-00252-y","volume":"20","author":"MM Attwood","year":"2021","unstructured":"Attwood MM, Fabbro D, Sokolov AV, Knapp S, Schi\u00f6th HB. Trends in kinase drug discovery: targets, indications and inhibitor design. Nat Rev Drug Discov. 2021;20:839\u201361.","journal-title":"Nat Rev Drug Discov"},{"key":"3031_CR59","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1038\/s41573-020-0078-4","volume":"19","author":"MM Attwood","year":"2020","unstructured":"Attwood MM, Jonsson J, Rask-Andersen M, Schi\u00f6th HB. Soluble ligands as drug targets. Nat Rev Drug Discov. 2020;19:695\u2013710.","journal-title":"Nat Rev Drug Discov"},{"key":"3031_CR60","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-022-02148-w","volume":"12","author":"F Dijkstra","year":"2022","unstructured":"Dijkstra F, O\u2019Donnell P, Klaassen E, Buhl D, Asgharnejad M, Rosen L, et al. Central nervous system effects of TAK-653, an investigational alpha-amino-3-hydroxy-5- methyl-4-isoxazole receptor (AMPAR) positive allosteric modulator in healthy volunteers. Transl Psychiatry 2022;12:408.","journal-title":"Transl Psychiatry"},{"key":"3031_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-023-02557-5","volume":"13","author":"K Recourt","year":"2023","unstructured":"Recourt K, de Boer P, van der Ark P, Benes H, van Gerven JM, Ceusters M, et al. Characterization of the central nervous system penetrant and selective purine P2X7 receptor antagonist JNJ-54175446 in patients with major depressive disorder. Transl Psychiatry 2023;13:266.","journal-title":"Transl Psychiatry"},{"key":"3031_CR62","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/S0140-6736(04)17034-7","volume":"364","author":"C De Angelis","year":"2004","unstructured":"De Angelis C, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R, et al. Clinical trial registration: a statement from the International Committee of Medical Journal Editors. Lancet. 2004;364:911\u20132.","journal-title":"Lancet"},{"key":"3031_CR63","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1111\/j.1756-5391.2011.01147.x","volume":"4","author":"LM Askie","year":"2011","unstructured":"Askie LM. Australian New Zealand Clinical Trials Registry: history and growth. J Evid Based Med. 2011;4:185\u20137.","journal-title":"J Evid Based Med."},{"key":"3031_CR64","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1007\/s11136-018-2080-4","volume":"28","author":"R Mercieca-Bebber","year":"2019","unstructured":"Mercieca-Bebber R, Williams D, Tait MA, Rutherford C, Busija L, Roberts N, et al. International Society for Quality of Life Research (ISOQOL) Australia and New Zealand Special Interest Group. Trials with proxy-reported outcomes registered on the Australian New Zealand Clinical Trials Registry (ANZCTR). Qual Life Res. 2019;28:955\u201362.","journal-title":"Qual Life Res"},{"key":"3031_CR65","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.1007\/s11136-018-1921-5","volume":"27","author":"R Mercieca-Bebber","year":"2018","unstructured":"Mercieca-Bebber R, Williams D, Tait MA, Roydhouse J, Busija L, Sundaram CS, et al. Trials with patient-reported outcomes registered on the Australian New Zealand Clinical Trials Registry (ANZCTR). Qual Life Res. 2018;27:2581\u201391.","journal-title":"Qual Life Res"},{"key":"3031_CR66","doi-asserted-by":"publisher","first-page":"e0279926","DOI":"10.1371\/journal.pone.0279926","volume":"18","author":"M Showell","year":"2023","unstructured":"Showell M, Buckman S, Berber S, Ata Allah N, Patterson B, Cole S, et al. Publication bias in trials registered in the Australian New Zealand Clinical Trials Registry: Is it a problem? A cross-sectional study. PLoS ONE. 2023;18:e0279926.","journal-title":"PLoS ONE"},{"key":"3031_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2020.103491","volume":"108","author":"L Houston","year":"2020","unstructured":"Houston L, Yu P, Martin A, Probst Y. Heterogeneity in clinical research data quality monitoring: a national survey. Biomed Inform. 2020;108:103491.","journal-title":"Biomed Inform"},{"key":"3031_CR68","doi-asserted-by":"publisher","DOI":"10.1002\/jbt.22410","volume":"33","author":"M Ghiasian","year":"2019","unstructured":"Ghiasian M, Khamisabadi F, Kheiripour N, Karami M, Haddadi R, Ghaleiha A, et al. Effects of crocin in reducing DNA damage, inflammation, and oxidative stress in multiple sclerosis patients: A double\u2010 blind, randomized, and placebo\u2010 controlled trial. J Biochem Mol Toxicol 2019;33:e22410.","journal-title":"J Biochem Mol Toxicol"},{"key":"3031_CR69","doi-asserted-by":"publisher","first-page":"e001158","DOI":"10.1136\/bmjgast-2023-001158","volume":"10","author":"S Razdar","year":"2023","unstructured":"Razdar S, Panahi Y, Mohammadi R, Khedmat L, Khedmat H. Evaluation of the efficacy and safety of an innovative flavonoid lotion in patients with haemorrhoid: a randomised clinical trial. BMJ Open Gastroenterol. 2023;10:e001158.","journal-title":"BMJ Open Gastroenterol"},{"key":"3031_CR70","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2022.115591","volume":"10","author":"A Sahoo","year":"2022","unstructured":"Sahoo A, Jena AK, Panda M. Experimental and clinical trial investigations of phyto-extracts, phyto- chemicals and phyto-formulations in the treatment of oral lichen planus: a systematic review. J Ethnopharmacol 2022;10:115591.","journal-title":"J Ethnopharmacol"},{"key":"3031_CR71","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1001\/jama.2014.15939","volume":"313","author":"H Moses","year":"2015","unstructured":"Moses H, Matheson DH, Cairns-Smith S, George BP, Palisch C, Dorsey ER. The anatomy of medical research: US and international comparisons. JAMA. 2015;313:174\u201389.","journal-title":"JAMA"},{"key":"3031_CR72","doi-asserted-by":"crossref","unstructured":"Huang J, He Y, Su Q, Yang J. Characteristics of COVID-19 clinical trials in China based on the registration data on ChiCTR and ClinicalTrials. gov. Drug Des Devel Ther. 2020:2159\u201364.","DOI":"10.2147\/DDDT.S254354"},{"key":"3031_CR73","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1080\/22221751.2020.1791736","volume":"9","author":"P Xu","year":"2020","unstructured":"Xu P, Xing X, Yu K, Lv Z, Cui H, Shi Y, et al. Profiles of COVID-19 clinical trials in the Chinese Clinical Trial Registry. Emerg Microbes Infect. 2020;9:1695\u2013701.","journal-title":"Emerg Microbes Infect"},{"key":"3031_CR74","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1002\/cai2.58","volume":"2","author":"Y Cao","year":"2023","unstructured":"Cao Y, Ye LM, Fan Z, Yang W, Chen LY, Mei Y, et al. The landscape of investigator\u2010 initiated oncology trials conducted in mainland China during the past decade (2010\u20132019). Cancer Innov. 2023;2:79\u201390.","journal-title":"Cancer Innov"},{"key":"3031_CR75","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-0280-y","volume":"10","author":"S Liu","year":"2020","unstructured":"Liu S, Deng B, Yin Z, Pan J, Lin Y, Ling Z, et al. Corticosteroids do not influence the efficacy and kinetics of CAR-T cells for B-cell acute lymphoblastic leukemia. Blood Cancer J. 2020;10:15.","journal-title":"Blood Cancer J"},{"key":"3031_CR76","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1002\/hup.2475","volume":"30","author":"CM Coyle","year":"2015","unstructured":"Coyle CM, Laws KR. The use of ketamine as an antidepressant: a systematic review and meta\u2010 analysis. Hum Psychopharmacol: Clin Exp. 2015;30:152\u201363.","journal-title":"Hum Psychopharmacol: Clin Exp"},{"key":"3031_CR77","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1177\/0269881113478283","volume":"27","author":"KG Rasmussen","year":"2013","unstructured":"Rasmussen KG, Lineberry TW, Galardy CW, Kung S, Lapid MI, Palmer BA, et al. Serial infusions of low-dose ketamine for major depression. J Psychopharmacol 2013;27:444\u201350.","journal-title":"J Psychopharmacol"},{"key":"3031_CR78","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s44192-022-00012-3","volume":"2","author":"M Yavi","year":"2022","unstructured":"Yavi M, Lee H, Henter ID, Park LT, Zarate CA Jr. Ketamine treatment for depression: a review. Discov Ment Health. 2022;2:9.","journal-title":"Discov Ment Health"},{"key":"3031_CR79","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/S2215-0366(22)00317-0","volume":"9","author":"SY Smith-Apeldoorn","year":"2022","unstructured":"Smith-Apeldoorn SY, Veraart JK, Spijker J, Kamphuis J, Schoevers RA. Maintenance ketamine treatment for depression: a systematic review of efficacy, safety, and tolerability. Lancet Psychiatry. 2022;9:907\u201321.","journal-title":"Lancet Psychiatry"},{"key":"3031_CR80","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1177\/0004867413486842","volume":"47","author":"N Katalinic","year":"2013","unstructured":"Katalinic N, Lai R, Somogyi A, Mitchell PB, Glue P, Loo CK. Ketamine as a new treatment for depression: a review of its efficacy and adverse effects. Aust N Z J Psychiatry. 2013;47:710\u201327.","journal-title":"Aust N Z J Psychiatry"},{"key":"3031_CR81","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2022.109305","volume":"222","author":"K Zhang","year":"2023","unstructured":"Zhang K, Yao Y, Hashimoto K. Ketamine and its metabolites: potential as novel treatments for depression. Neuropharmacology. 2023;222:109305.","journal-title":"Neuropharmacology"},{"key":"3031_CR82","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.12669\/pjms.38.5.5230","volume":"38","author":"S Shao","year":"2022","unstructured":"Shao S, Sun B, Sun H. Clinical efficacy of vortioxetine and escitalopram in the treatment of depression. Pak J Med Sci. 2022;38:1389.","journal-title":"Pak J Med Sci"},{"key":"3031_CR83","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.pnpbp.2017.03.016","volume":"80","author":"P Ga\u0142ecki","year":"2018","unstructured":"Ga\u0142ecki P, Mossakowska-W\u00f3jcik J, Talarowska M. The anti-inflammatory mechanism of antidepressants\u2013SSRIs, SNRIs. Prog Neuropsychopharmacol Biol Psychiatry. 2018;80:291\u20134.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"3031_CR84","doi-asserted-by":"publisher","DOI":"10.1016\/j.mehy.2020.110140","volume":"144","author":"MG Hamed","year":"2020","unstructured":"Hamed MG, Hagag RS. The possible immunoregulatory and anti-inflammatory effects of selective serotonin reuptake inhibitors in coronavirus disease patients. Med Hypotheses. 2020;144:110140.","journal-title":"Med Hypotheses"},{"key":"3031_CR85","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.bbi.2019.06.001","volume":"81","author":"R Hou","year":"2019","unstructured":"Hou R, Ye G, Liu Y, Chen X, Pan M, Zhu F, et al. Effects of SSRIs on peripheral inflammatory cytokines in patients with Generalized Anxiety Disorder. Brain Behav Immun. 2019;81:105\u201310.","journal-title":"Brain Behav Immun"},{"key":"3031_CR86","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.euroneuro.2013.12.006","volume":"24","author":"F Tyl\u0161","year":"2014","unstructured":"Tyl\u0161 F, P\u00e1len\u00ed\u010dek T, Hor\u00e1\u010dek J. Psilocybin\u2013summary of knowledge and new perspectives. Eur Neuropsychopharmacol. 2014;24:342\u201356.","journal-title":"Eur Neuropsychopharmacol"},{"key":"3031_CR87","doi-asserted-by":"publisher","first-page":"2948","DOI":"10.3390\/molecules26102948","volume":"26","author":"H Lowe","year":"2021","unstructured":"Lowe H, Toyang N, Steele B, Valentine H, Grant J, Ali A, et al. The therapeutic potential of psilocybin. Molecules. 2021;26:2948.","journal-title":"Molecules"},{"key":"3031_CR88","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1080\/14737175.2016.1220834","volume":"17","author":"BT De Veen","year":"2017","unstructured":"De Veen BT, Schellekens AF, Verheij MM, Homberg JR. Psilocybin for treating substance use disorders? Expert Rev Neurother. 2017;17:203\u201312.","journal-title":"Expert Rev Neurother"},{"key":"3031_CR89","doi-asserted-by":"publisher","first-page":"331","DOI":"10.3390\/biomedicines8090331","volume":"8","author":"AS Vargas","year":"2020","unstructured":"Vargas AS, Lu\u00eds \u00c2, Barroso M, Gallardo E, Pereira L. Psilocybin as a new approach to treat depression and anxiety in the context of life-threatening diseases\u2014a systematic review and meta-analysis of clinical trials. Biomedicines. 2020;8:331.","journal-title":"Biomedicines"},{"key":"3031_CR90","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1056\/NEJMoa2206443","volume":"387","author":"GM Goodwin","year":"2022","unstructured":"Goodwin GM, Aaronson ST, Alvarez O, Arden PC, Baker A, Bennett JC, et al. Single-dose psilocybin for a treatment-resistant episode of major depression. N Engl J Med. 2022;387:1637\u201348.","journal-title":"N Engl J Med"},{"key":"3031_CR91","doi-asserted-by":"crossref","unstructured":"von Rotz R, Schindowski EM, Jungwirth J, Schuldt A, Rieser NM, Zahoranszky K, et al. Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial. EClinicalMedicine. 2023;56:101809.","DOI":"10.1016\/j.eclinm.2022.101809"},{"key":"3031_CR92","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jad.2021.09.041","volume":"296","author":"NX Li","year":"2022","unstructured":"Li NX, Hu YR, Chen WN, Zhang B. Dose effect of psilocybin on primary and secondary depression: a preliminary systematic review and meta-analysis. J Affect Disord. 2022;296:26\u201334.","journal-title":"J Affect Disord"},{"key":"3031_CR93","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","volume":"384","author":"R Carhart-Harris","year":"2021","unstructured":"Carhart-Harris R, Giribaldi B, Watts R, Baker-Jones M, Murphy-Beiner A, Murphy R, et al. Trial of psilocybin versus escitalopram for depression. N Engl J Med. 2021;384:1402\u201311.","journal-title":"N Engl J Med"},{"key":"3031_CR94","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.euroneuro.2023.07.011","volume":"76","author":"N Perez","year":"2023","unstructured":"Perez N, Langlest F, Mallet L, De Pieri M, Sentissi O, Thorens G, et al. Psilocybin-assisted therapy for depression: a systematic review and dose-response meta-analysis of human studies. Eur Neuropsychopharmacol. 2023;76:61\u201376.","journal-title":"Eur Neuropsychopharmacol"},{"key":"3031_CR95","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.clnesp.2023.02.025","volume":"55","author":"S Abbasi","year":"2023","unstructured":"Abbasi S, Sigari AA, Rostami S, Sedaghat N, Tavakoli R. Effect of enteral probiotics on prognostic scores and C-reactive protein levels in critically ill multiple trauma patients: A randomized, double-blind, placebo-controlled clinical trial. Clin Nutr ESPEN. 2023;55:30\u201337.","journal-title":"Clin Nutr ESPEN"},{"key":"3031_CR96","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s13098-022-00822-z","volume":"14","author":"F Ahmadian","year":"2022","unstructured":"Ahmadian F, Razmpoosh E, Ejtahed HS, Javadi M, Mirmiran P, Azizi F. Effects of probiotic supplementation on major cardiovascular-related parameters in patients with type-2 diabetes mellitus: a secondary-data analysis of a randomized double-blind controlled trial. Diabetol Metab Syndr. 2022;14:52.","journal-title":"Diabetol Metab Syndr"},{"key":"3031_CR97","first-page":"141","volume":"27","author":"N Salarkia","year":"2013","unstructured":"Salarkia N, Ghadamli L, Zaeri F, Rad LS. Effects of probiotic yogurt on performance, respiratory and digestive systems of young adult female endurance swimmers: a randomized controlled trial. Med J Islamic Repub Iran. 2013;27:141.","journal-title":"Med J Islamic Repub Iran"},{"key":"3031_CR98","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/S0924-977X(03)00032-4","volume":"13","author":"KP Su","year":"2003","unstructured":"Su KP, Huang SY, Chiu CC, Shen WW. Omega-3 fatty acids in major depressive disorder: a preliminary double-blind, placebo-controlled trial. Eur Neuropsychopharmacol. 2003;13:267\u201371.","journal-title":"Eur Neuropsychopharmacol"},{"key":"3031_CR99","doi-asserted-by":"publisher","first-page":"74","DOI":"10.4103\/jpgm.JPGM_571_17","volume":"65","author":"F Vellekkatt","year":"2019","unstructured":"Vellekkatt F, Menon V. Efficacy of vitamin D supplementation in major depression: a meta-analysis of randomized controlled trials. J Postgrad Med. 2019;65:74.","journal-title":"J Postgrad Med"},{"key":"3031_CR100","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.3390\/nu12061661","volume":"12","author":"A Botturi","year":"2020","unstructured":"Botturi A, Ciappolino V, Delvecchio G, Boscutti A, Viscardi B, Brambilla P. The role and the effect of magnesium in mental disorders: a systematic review. Nutrients. 2020;12:1661.","journal-title":"Nutrients"},{"key":"3031_CR101","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1037\/a0038550","volume":"23","author":"TM Hillhouse","year":"2015","unstructured":"Hillhouse TM, Porter JH. A brief history of the development of antidepressant drugs: from monoamines to glutamate. Exp Clin Psychopharmacol. 2015;23:1.","journal-title":"Exp Clin Psychopharmacol"},{"key":"3031_CR102","doi-asserted-by":"crossref","unstructured":"Al-Harbi KS. Treatment-resistant depression: therapeutic trends, challenges, and future directions. Patient Prefer Adherence. 2012;6:369\u201388.","DOI":"10.2147\/PPA.S29716"},{"key":"3031_CR103","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s40263-021-00816-x","volume":"35","author":"ID Henter","year":"2021","unstructured":"Henter ID, Park LT, Zarate CA Jr. Novel glutamatergic modulators for the treatment of mood disorders: current status. CNS Drugs. 2021;35:527\u201343.","journal-title":"CNS Drugs"},{"key":"3031_CR104","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1038\/mp.2013.130","volume":"19","author":"G Sanacora","year":"2014","unstructured":"Sanacora G, Smith MA, Pathak S, Su HL, Boeijinga PH, McCarthy DJ, et al. Lanicemine: a low- trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects. Mol Psychiatry. 2014;19:978\u201385.","journal-title":"Mol Psychiatry"},{"key":"3031_CR105","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1002\/da.23194","volume":"38","author":"N Ramakrishnan","year":"2021","unstructured":"Ramakrishnan N, Lijffijt M, Green CE, Balderston NL, Murphy N, Grillon C, et al. Neurophysiological and clinical effects of the NMDA receptor antagonist lanicemine (BHV\u2010 5500) in PTSD: a randomized, double\u2010blind, placebo\u2010controlled trial. Depression Anxiety. 2021;38:1108\u201319.","journal-title":"Depression Anxiety"},{"key":"3031_CR106","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.bbr.2016.10.050","volume":"319","author":"SA Robinson","year":"2017","unstructured":"Robinson SA, Erickson RL, Browne CA, Lucki I. A role for the mu opioid receptor in the antidepressant effects of buprenorphine. Behav Brain Res. 2017;319:96\u2013103.","journal-title":"Behav Brain Res"},{"key":"3031_CR107","doi-asserted-by":"crossref","unstructured":"Zajecka JM, Stanford AD, Memisoglu A, Martin WF, Pathak S. Buprenorphine\/samidorphan combination for the adjunctive treatment of major depressive disorder: results of a phase III clinical trial (FORWARD-3). Neuropsychiatr Dis Treat. 2019;15:795\u2013808.","DOI":"10.2147\/NDT.S199245"},{"key":"3031_CR108","doi-asserted-by":"publisher","first-page":"40618","DOI":"10.4088\/JCP.21m14140","volume":"83","author":"PJ Na","year":"2022","unstructured":"Na PJ, Scodes J, Fishman M, Rotrosen J, Nunes EV Jr. Co-occurring depression and suicidal ideation in opioid use disorder: prevalence and response during treatment with buprenorphine-naloxone and injection naltrexone. J Clin Psychiatry. 2022;83:40618.","journal-title":"J Clin Psychiatry"},{"key":"3031_CR109","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.pbb.2010.05.006","volume":"96","author":"DH Overstreet","year":"2010","unstructured":"Overstreet DH, Naimoli VM, Griebel G. Saredutant, an NK2 receptor antagonist, has both antidepressant-like effects and synergizes with desipramine in an animal model of depression. Pharmacol Biochem Behav. 2010;96:206\u201310.","journal-title":"Pharmacol Biochem Behav"},{"key":"3031_CR110","first-page":"1","volume":"34","author":"JG Winner","year":"2022","unstructured":"Winner JG, Anusha N. Plasma Kinins- A Pharmacological Perspective. J Pharm Res Int. 2022;34:1\u201315.","journal-title":"J Pharm Res Int"},{"key":"3031_CR111","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1077514","volume":"13","author":"M Li","year":"2023","unstructured":"Li M, Ma H, Zhang S, Peng Y, Ding L, Zhang Y, et al. Potential therapeutic effect of NK1R antagonist in diabetic non-healing wound and depression. Front Endocrinol. 2023;13:1077514.","journal-title":"Front Endocrinol"},{"key":"3031_CR112","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1093\/ijnp\/pyab078","volume":"25","author":"MK Jha","year":"2022","unstructured":"Jha MK. Selective orexin receptor antagonists as novel augmentation treatments for major depressive disorder: evidence for safety and efficacy from a phase 2B study of seltorexant. Int J Neuropsychopharmacol 2022;25:85\u20138.","journal-title":"Int J Neuropsychopharmacol"},{"key":"3031_CR113","doi-asserted-by":"crossref","unstructured":"Wilson CA, Robertson L, Brown JV, Ayre K, Khalifeh H. Brexanolone and related neurosteroid GABA (A) positive allosteric modulators for postnatal depression. Cochrane Database Syst Revs. 2021;2021:CD014624.","DOI":"10.1002\/14651858.CD014624"},{"key":"3031_CR114","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1176\/appi.ajp.20220785","volume":"180","author":"KM Deligiannidis","year":"2023","unstructured":"Deligiannidis KM, Meltzer-Brody S, Maximos B, Peeper EQ, Freeman M, Lasser R, et al. Zuranolone for the treatment of postpartum depression. Am J Psychiatry. 2023;180:668\u201375.","journal-title":"Am J Psychiatry"},{"key":"3031_CR115","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.jad.2023.08.027","volume":"340","author":"S Meshkat","year":"2023","unstructured":"Meshkat S, Teopiz KM, Di Vincenzo JD, Bailey JB, Rosenblat JD, Ho RC, et al. Clinical efficacy and safety of Zuranolone (SAGE-217) in individuals with major depressive disorder. J Affect Disord. 2023;340:893\u20138.","journal-title":"J Affect Disord"},{"key":"3031_CR116","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.tips.2023.06.009","volume":"44","author":"B Luscher","year":"2023","unstructured":"Luscher B, Maguire JL, Rudolph U, Sibille E. GABAA receptors as targets for treating affective and cognitive symptoms of depression. Trends Pharmacol Sci. 2023;44:586\u2013600.","journal-title":"Trends Pharmacol Sci"},{"key":"3031_CR117","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1002\/phar.2707","volume":"42","author":"TJ Moore","year":"2022","unstructured":"Moore TJ, Alami A, Alexander GC, Mattison DR. Safety and effectiveness of NMDA receptor antagonists for depression: A multidisciplinary review. Pharmacotherapy: J Hum Pharmacol Drug Ther. 2022;42:567\u201379.","journal-title":"Pharmacotherapy: J Hum Pharmacol Drug Ther"},{"key":"3031_CR118","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1080\/14737175.2019.1643237","volume":"19","author":"B Pochwat","year":"2019","unstructured":"Pochwat B, Nowak G, Szewczyk B. An update on NMDA antagonists in depression. Expert Rev Neurother. 2019;19:1055\u201367.","journal-title":"Expert Rev Neurother"},{"key":"3031_CR119","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s00406-019-01084-z","volume":"271","author":"U Kaur","year":"2021","unstructured":"Kaur U, Pathak BK, Singh A, Chakrabarti SS. Esketamine: a glimmer of hope in treatment-resistant depression. Eur Arch Psychiatry Clin Neurosci. 2021;271:417\u201329.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"3031_CR120","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1056\/NEJMoa2304145","volume":"389","author":"A Reif","year":"2023","unstructured":"Reif A, Bitter I, Buyze J, Cebulla K, Frey R, Fu DJ, et al. Esketamine nasal spray versus quetiapine for treatment-resistant depression. N Engl J Med. 2023;389:1298\u2013309.","journal-title":"N Engl J Med"}],"container-title":["Translational Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41398-024-03031-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-024-03031-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-024-03031-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T19:22:23Z","timestamp":1722453743000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41398-024-03031-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,31]]},"references-count":120,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3031"],"URL":"https:\/\/doi.org\/10.1038\/s41398-024-03031-6","relation":{},"ISSN":["2158-3188"],"issn-type":[{"value":"2158-3188","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,31]]},"assertion":[{"value":"19 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"315"}}